Saudi Journal of Medicine and Medical Sciences

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 5  |  Issue : 3  |  Page : 218--223

Evaluation of response to hepatitis B vaccination in chronic hemodialysis patients


Samir H Almueilo 
 Department of Internal Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Al Khobar, Saudi Arabia

Correspondence Address:
Samir H Almueilo
King Fahd Hospital of the University, P. O. Box 40154, Al Khobar 31952
Saudi Arabia

Background: Hemodialysis (HD) patients are at an increased risk of acquiring hepatitis B virus (HBV) infection. Active HBV immunization in these patients is recommended. A response rate in HD patients is variable but generally lower than healthy individuals. Objective: The aim of this study is to assess the response of HD patients to the HBV vaccine and correlate response and long-term immunity to various clinical and biomedical factors. Patients and Methods: One hundred and one patients, with a mean age 48.7 ± 18.5 years, received 40 μg of HBV vaccine administered intramuscularly in the deltoid region at 0, 1, 2 and 6 months. The patients' responses to the vaccine were determined by measuring hepatitis B surface antibody (HBsAb) 6 weeks after the last injection and monitored thereafter at 3-month intervals. Results: Seventy-one patients (70.3%) mounted a response with HBsAb >10 mIU/ml 6 weeks following the fourth dose of vaccine, and thus were considered considered as adequate responders. Forty-nine (48.5%) patients mounted an excellent response with HBsAb >100 mIU/ml 6 weeks after the fourth dose. Thirty patients (29.7%) were nonresponders. Responders were significantly younger than nonresponders (P = 0.01). Gender, hemoglobin level, serum albumin, ferritin, parathyroid hormone level and hepatitis C virus infection had no effect on the response to the vaccine. Similarly, there was no difference in diabetic state and adequacy of HD between the two groups. Fifty-nine patients (88%) had persistent protective antibodies at 1 year, while eight (12%) lost such protection. Predictors of persistent immunity at 1 year were high HBsAb level at the completion of the vaccination regime and, to a lesser extent, young age. Conclusion: A 70% response rate to HBV vaccine was observed in the cohort of this study. Young age predicts a favorable response to HBV vaccine in HD patients. High (>100 mIU/ml) HBsAb levels achieved at vaccine completion predict persistent immunity at 1 year.


How to cite this article:
Almueilo SH. Evaluation of response to hepatitis B vaccination in chronic hemodialysis patients.Saudi J Med Med Sci 2017;5:218-223


How to cite this URL:
Almueilo SH. Evaluation of response to hepatitis B vaccination in chronic hemodialysis patients. Saudi J Med Med Sci [serial online] 2017 [cited 2023 Feb 7 ];5:218-223
Available from: https://www.sjmms.net/article.asp?issn=1658-631X;year=2017;volume=5;issue=3;spage=218;epage=223;aulast=Almueilo;type=0